摘要
目的:评价重组人促红细胞生成素(recombinanthumanerythropoietin熏rHuEPO)治疗癌性贫血的疗效和安全性。方法:非髓性癌性贫血患者46例,皮下注射rHuEPO150U/kg,每周3次,连续8周,同时化疗至少2周期。比较治疗前后血红蛋白(HB)、红细胞压积(Hct)水平,评价体力状态和生活质量的变化以及药物不良反应。结果:44例可评价血液学反应,其中23例穴52.3%雪HB上升≥20g/L或HB≥120g/L,Hct值也明显上升(P<0.05)。体力状态0鄄2级的患者较rHuEPO治疗前增加5例,QOL评分略微增加穴P>0.05雪,8例患者疲劳程度减轻。粒细胞减少、消化道反应等不良反应多与化疗相关。结论:rHuEPO能明显提高非髓性癌性贫血患者化疗时的HB水平,改善体力状态和生活质量,提高化疗耐受性,副作用少且使用安全。
Objective: To evaluate the safety and efficacy of recombinant human erythropoietin (rHuEPO) for anemic cancer patients receiving chemotherapy. Methods: A total of 46 anemic non-myeloid cancer patients under chemotherapy were enrolled into this study. Patients received rHuEPO at a dose of 150U/kg subcutaneously TIW for 8 weeks. Patients' HB, Hct, performance status and quality of life (QOL) before and after rHuEPO treatment were compared and the adverse events were recorded. Results: Among the 44 patients evaluable for hematological response, 23 (52.3%) had an increase in HB≥20g/L or displayed HB≥120g/L (P<0.05).The same is in Hct. Five others had a performance status of 0-2 grade and a slightly improved QOL(P>0.05). Eight patients experienced less fatigue. Neutropenia, nausia and emesis mostly resulted from chemotherapy. Conclusion: rHuEPO increases HB, and improves performance status and QOL in anemic non-myeloid cancer patients under chemotherapy with limited advevse etfects.
出处
《山东大学学报（医学版）》
CAS
2004年第6期684-686,共3页
Journal of Shandong University:Health Sciences
关键词
贫血
癌
药物疗法
重组人促红细胞生成素
生活质量
Anemia
Cancer
Drug therapy
Recombinant human erythropoietin
Quality of life
